company background image
SLRN logo

Acelyrin NasdaqGS:SLRN Stock Report

Last Price

US$8.34

Market Cap

US$794.3m

7D

9.2%

1Y

n/a

Updated

28 Feb, 2024

Data

Company Financials +

SLRN Stock Overview

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines.

SLRN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Acelyrin, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Acelyrin
Historical stock prices
Current Share PriceUS$8.34
52 Week HighUS$29.88
52 Week LowUS$5.70
Beta0
1 Month Change11.20%
3 Month Change24.11%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-64.51%

Recent News & Updates

Recent updates

Shareholder Returns

SLRNUS BiotechsUS Market
7D9.2%4.7%2.1%
1Yn/a11.8%26.0%

Return vs Industry: Insufficient data to determine how SLRN performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how SLRN performed against the US Market.

Price Volatility

Is SLRN's price volatile compared to industry and market?
SLRN volatility
SLRN Average Weekly Movement11.0%
Biotechs Industry Average Movement11.8%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: SLRN's share price has been volatile over the past 3 months.

Volatility Over Time: SLRN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2020108Shao-Lee Linhttps://www.acelyrin.com

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company’s lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria.

Acelyrin, Inc. Fundamentals Summary

How do Acelyrin's earnings and revenue compare to its market cap?
SLRN fundamental statistics
Market capUS$794.29m
Earnings (TTM)-US$306.24m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SLRN income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$306.24m
Earnings-US$306.24m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-3.15
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did SLRN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.